Brian Wiethop
Endocrinology, Diabetes & Metabolism · Dothan, ALNPI 1851375679
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.6% of the total across 151 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 13.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $713 and has fallen 97.5% since, to $18 in 2024. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in AL, where the typical reported total is $6,650.
Across 151 payments — averaging $15.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dexcom, Inc.$321
- Novo Nordisk$300
- Abbott$200
- AbbVie$180
- Johnson & Johnson$162
- Amarin Pharma, Inc.$156
- plus $1K from 24 others
What the payments were for
- Food & beverage$2,30698%
- Education$50%
- Other$522%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dexcom, Inc. | 26 | $321 |
| Novo Nordisk | 23 | $300 |
| Abbott | 16 | $200 |
| AbbVie | 9 | $180 |
| Johnson & Johnson | 7 | $162 |
| Amarin Pharma, Inc. | 10 | $156 |
| Corcept Therapeutics | 11 | $154 |
| Esperion Therapeutics, Inc. | 3 | $152 |
| Sanofi-aventis U.S. LLC | 6 | $115 |
| Bayer | 7 | $98 |
| Boehringer Ingelheim | 5 | $82 |
| Xeris Pharmaceuticals, Inc. | 3 | $47 |
| Shire North American Group Inc | 3 | $45 |
| Ultragenyx Pharmaceutical Inc. | 2 | $41 |
| Ipsen Biopharmaceuticals, Inc | 2 | $36 |
| ANI Pharmaceuticals, Inc. | 2 | $32 |
| Insulet Corporation | 1 | $28 |
| Baxter Healthcare | 1 | $26 |
| Welch Allyn | 1 | $26 |
| Lilly USA, LLC | 2 | $23 |
| Eisai Inc. | 2 | $23 |
| AstraZeneca | 1 | $15 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
| GRT US Holding, Inc. | 1 | $14 |
| Biohaven Pharmaceuticals, Inc. | 1 | $13 |
| Medtronic | 1 | $13 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $12 |
| Merck | 1 | $12 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
| Amgen | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,363 in reported general payments places this provider in the 25th percentile of 79 endocrinology, diabetes & metabolism providers in Alabama.
See all endocrinology, diabetes & metabolism providers in Alabama →
Other endocrinology, diabetes & metabolism in Dothan
- Bruce TrippeDothan$68K
- Steven WiseDothan$3K
- John StoneDothan$3K
- Neil SchaffnerOpelika$642K
- Ralph TeagueBirmingham$487K
- Bantwal BaligaOpelika$483K
- William GarveyBirmingham$421K
- Judson MenefeeFairhope$168K
- William DebellTuscaloosa$161K
- Edison GoncalvesBirmingham$142K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.